Ismelin Side Effects
Generic name: guanethidine
Medically reviewed by Drugs.com. Last updated on Feb 12, 2022.
Note: This document contains side effect information about guanethidine. Some of the dosage forms listed on this page may not apply to the brand name Ismelin.
Applies to guanethidine: oral tablet
The risk of orthostatic hypotension, sometimes followed by syncope, is greatest within the first 10 minutes after dosing, early in the morning, and in hypovolemic patients. It is accentuated by alcohol, hot weather, or exercise--all of which are associated with peripheral vasodilation. The manufacturer recommends that guanethidine (the active ingredient contained in Ismelin) be gradually withdrawn over at least two weeks prior to administration of general anesthetics to avoid cardiovascular collapse during induction.[Ref]
Cardiovascular side effects can result from excessive sympathetic blockade or a relative increase in parasympathetic tone. Orthostatic hypotension is reported in approximately 15% of patients, some of whom experience syncope.
Gastrointestinal side effects are also related to increased parasympathetic tone. Diarrhea is reported in 11% of patients, some of whom discontinued therapy because of it. Dry mouth or parotid tenderness are reported in approximately 5% of patients.[Ref]
There is evidence that guanethidine (the active ingredient contained in Ismelin) may interfere with ejaculation by inhibiting contraction of the seminal vesicle, ampula and ductus deferens.[Ref]
Large studies report sexual impotence as a relatively uncommon genitourinary complaint, occurring in only approximately 2% of male patients. Smaller studies, where specific questions were asked of male patients reveal an incidence of impotence as high as 60%. Delayed or retrograde ejaculation and decreased sperm counts are reported. Impotence appears to be reversible upon discontinuation of therapy or reduction in dosage.[Ref]
A relatively common respiratory system complaint, nasal stuffiness in up to 30% of patients, is related to increased parasympathetic tone. Rare reports of dyspnea or exertion unaccompanied by other signs or symptoms of congestive heart failure are associated with guanethidine (the active ingredient contained in Ismelin) [Ref]
In one study, 58% of patients with or without preexisting elevated BUN developed an increase in the BUN during guanethidine (the active ingredient contained in Ismelin) therapy. The study did not, however, quantify the rise in BUN, attempt to make an association with the degree of blood pressure control, or attempt to measure other parameters of renal function.[Ref]
Because guanethidine (the active ingredient contained in Ismelin) does not affect the central nervous system, neurologic side effects are notably either absent or infrequent. Insomnia and weakness are occasionally reported more often with guanethidine than with placebo.[Ref]
Hypersensitivity reactions are not associated with guanethidine (the active ingredient contained in Ismelin) [Ref]
More about Ismelin (guanethidine)
- Drug interactions
- Dosage information
- During pregnancy
- Drug images
- Drug class: antiadrenergic agents, peripherally acting
Related treatment guides
1. Dollery CT, Emslie-Smith D, Milne MD "Clinical and pharmacological studies with guanethidine in the treatment of hypertension." Lancet Aug (1960): 381-7
2. Goldberg LI, Zimmerman AM "Guanethidine and methyldopa as therapeutic agents in hypertension: a comparative review." Postgrad Med June (1963): 548-54
3. Leishman AW, Sandler G "Guanethidine and hypertension after five years." Angiology 18 (1967): 705-16
4. Weil JV, Chidsey CA "Plasma volume expansion resulting from interference with adrenergic function in normal man." Circulation 37 (1968): 54-61
5. Hansson L, Pascual A, Julius S "Comparison of guanadrel and guanethidine." Clin Pharmacol Ther 14 (1973): 204-8
6. Bulpitt CJ, Dollery CT "Side effects of hypotensive agents evaluated by a self-administered questionnaire." Br Med J 3 (1973): 485-90
7. Tarpley EL "Controlled trial of guanethidine and methyldopa in moderate hypertension." Curr Ther Res Clin Exp 16 (1974): 1187-96
8. Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974): 171-4
9. Adi FC, Eze CJ, Anwunah A "Comparison of debrisoquine and guanethidine in treatment of hypertension." Br Med J Mar (1975): 482-5
10. Woosley RL, Nies AS "Guanethidine." N Engl J Med 295 (1976): 1053-8
11. Walter IE, Nies AS "Safety of single large oral doses of guanethidine." Clin Pharmacol Ther 21 (1977): 706-8
12. Ramirez EA, Elson L, Freis ED, et al "Multiclinic controlled trial of bethanidine and guanethidine in severe hypertension." Circulation 55 (1977): 519-25
13. Scheinman MM, Strauss HC, Evans GT, et al "Adverse effects of sympatholytic agents in patients with hypertension and sinus node dysfunction." Am J Med 64 (1978): 1013-20
14. Rowe J, Bassan MM "Symptomatic sick sinus syndrome due to guanethidine." Hypertension 1 (1979): 543-6
15. Sharpe E, Milaszkiewicz R, Carli F "A case of prolonged hypotension following intravenous guanethidine block." Anaesthesia 42 (1987): 1081-4
16. Kalmanovitch DV, Hardwick PB "Hypotension after guanethidine block." Anaesthesia 43 (1988): 256
17. Malinow SH "Comparison of guanadrel and guanethidine efficacy and side effects." Clin Ther 5 (1983): 284-9
18. "Product Information. Ismelin (guanethidine)." Ciba Pharmaceuticals, Summit, NJ.
19. Jadad AR, Carroll D, Glynn CJ, Mcquay HJ "Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrophy: a systematic review and a randomized, double-blind crossover study." J Pain Symptom Manage 10 (1995): 13-20
20. Kaplan R, Claudio M, Kepes E, Gu XF "Intravenous guanethidine in patients with reflex sympathetic dystrophy." Acta Anaesthesiol Scand 40 (1996): 1216-22
21. Bauer GE, Hull RD, Stokes GS, Raftos J "The reversibility of side effects of guanethidine therapy." Med J Aust May (1973): 930-3
22. Kedia K, Markland C "The effect of pharmacological agents on ejaculation." J Urol 114 (1975): 569-73
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.